Remdesivir fact vs fiction Part 3: Approval process based on science or profit?, NIH Panel on COVID-19 Treatment Guidelines: 9 people on panel had financial ties to Gilead Sciences
Remdesivir fact vs fiction Part 3: Approval process based on science or profit?, NIH Panel on COVID-19 Treatment Guidelines: 9 people on panel had financial ties to Gilead Sciences
From NIH Covid-19 Treatment Guidelines.
”Potential Antiviral Drugs Under Evaluation for the Treatment of COVID-19
Throughout the section, study descriptions were updated to clearly indicate a study’s publication status and to provide an assessment of a study’s limitations and results. Data were also updated as needed based on changes to preprints or post-publication changes.
The following recommendations were added or revised in this section:
Remdesivir:
On the basis of preliminary clinical trial data, the Panel recommends the investigational antiviral agent remdesivir for the treatment of COVID-19 in hospitalized patients with severe disease, defined as SpO2 ≤94% on ambient air (at sea level), requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (BI).
Remdesivir is not approved by the Food and Drug Administration (FDA); however, it is available through an FDA emergency use authorization for the treatment of hospitalized adults and children with COVID-19. Remdesivir is also being investigated in clinical trials, and it is available through an emergency access program for children and pregnant patients.
The Panel does not recommend remdesivir for the treatment of mild or moderate COVID-19 outside the setting of a clinical trial (AIII).”
The following is a list of those people on the NIH Panel on COVID-19 Treatment Guidelines who had financial ties to Gilead Sciences, the manufacturer of Veklury® (remdesivir):
Rajesh Gandhi is on the advisory board of Gilead Sciences.
David Glidden is a consultant for Gilead Sciences.
Adaora Adimora is a consultant for Gilead Sciences and received research support from Gilead Sciences.
Eric Daar is a consultant for Gilead Sciences and recieves research support from Gilead Sciences.
Judith Aberg received research support from Gilead Sciences.
Jason Baker received research support from Gilead Sciences.
Susanna Naggie received research support from Gilead Sciences.
Pablo Tebas received research support from Gilead Sciences.
Roger Bedimo received an honoraria from Gilead Sciences.
